Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Bladder cancer stories

Oct 14, 2026

FDA expands Anktiva approval for bladder cancer treatment

The FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer, expanding the drug's approved indications.

Oct 14, 2026·2 sources
00
May 16, 2026

AstraZeneca's Imfinzi-Enfortumab Vedotin Combination Shows Historic Survival Gains in Bladder Cancer Trial

AstraZeneca's VOLGA trial confirms that the Imfinzi EV combination significantly improves overall survival for cisplatin-ineligible bladder cancer patients, representing a major advancement in treatment for this difficult-to-treat population.

May 16, 2026·1 source
00

Top claims

  • ▪Anktiva, a bladder cancer treatment, is administered at a 400 µg dose directly into the bladder via catheter alongside Bacillus Calmette-Guérin once weekly for 6 weeks as initial induction therapy
  • ▪The most common adverse reactions reported with Anktiva and Bacillus Calmette-Guérin treatment include dysuria, hematuria, urinary frequency, urinary tract infections, musculoskeletal pain, chills, pyrexia, and elevated creatinine
  • ▪FDA Oncology Center of Excellence director R. Angelo de Claro stated that review of shared cancer features allowed the agency to expand treatment options for papillary tumors

Topics

ImmunotherapyFDA drug approvalCancer treatment breakthroughsClinical Trial Design & EvaluationDrug Approval and Clinical TrialsPharmaClinical trialsClinical evaluationDrug Policy, Pricing & Approval

Related entities

Oncology